Bioasis to Attend and Present at Upcoming Industry Conferences
09. Dezember 2021 16:30 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Dec. 09, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™...
Bioasis Announces Annual General Meeting Details
29. November 2021 16:30 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Nov. 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021
28. Oktober 2021 17:50 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Oct. 28, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis to Attend Upcoming Industry Conferences
30. September 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Sept. 30, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™...
Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor
18. August 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Aug. 18, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfatase
09. August 2021 17:00 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
29. Juli 2021 16:28 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., July 29, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager
20. Juli 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., July 20, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple Sclerosis
07. Juli 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., July 07, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces the Appointment of Dave Jenkins as Chief Financial Officer
01. Juli 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., July 01, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...